Benzgalantamine

Summary

Benzgalantamine (CHEMBL5095056) is an approved small molecule; indicated across 2 conditions including alzheimer disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Chemistry: 391.5 Da · C24H25NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095056
Name	Benzgalantamine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	44240142
Molecular formula	C24H25NO4
Molecular weight	391.5
InChIKey	JKVNJTYHRABHIY-WXVUKLJWSA-N

SMILES: CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)OC(=O)C5=CC=CC=C5

IUPAC name: [(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] benzoate

Also known as: ALPHA-1062, Benzgalantamina, Benzgalantamine, Galantamine benzoate, GLN-1062, Memogain, BENZGALANTAMINE

Parent form; salt/anhydrous children: CHEMBL6068431

Patent coverage: 22 distinct patent families (53 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 37 (70%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Alzheimer disease	1	MONDO:0004975	MONDO:0004975

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).